Group 1 - Kiora Pharmaceuticals will participate in the Jones Trading Healthcare Seaside Summit on July 15, 2024, at 6:15 PM Eastern Time [10] - The company invites shareholders to submit questions regarding clinical development plans, investigational therapies, and financials through a dedicated Q&A portal from July 16 to July 19, 2024 [3] - The presentation will be available live and on-demand for 90 days on Kiora's Investor Relations homepage [6] Group 2 - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for orphan retinal diseases [7] - KIO-301 is being developed for retinitis pigmentosa, choroideremia, and Stargardt disease, aiming to restore vision in patients with retinal degeneration [7] - KIO-104 is being developed for posterior non-infectious uveitis as a next-generation, non-steroidal, immuno-modulatory small-molecule inhibitor [7]
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation